Begley S. ‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims — and finding some truth. STAT 2018:23 de agosto. [Ref.ID 102810]

Fuentes Camps I, Rodríguez A, Agustí A. Non-commercial vs. commercial clinical trials: a retrospective study of the applications submitted to a research ethics committee . Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102808]

Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 2018;391:30 de junio. [Ref.ID 102741]

Desjardins A, Gromeier M, Herndon II JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 2018;379:12 de juliol. [Ref.ID 102734]

Garde D. Alzheimer’s study sparks a new round of debate over the amyloid hypothesis. STAT Daily Recap 2018:30 de julio. [Ref.ID 102727]

Garde D. Experimental Alzheimer’s drug significantly slowed patients’ cognitive decline, buoying hopes for treatment. STAT Daily Recap 2018:1. [Ref.ID 102726]

Garde D. Biogen reports positive results with Alzheimer’s drug, reviving hopes for once-failed treatment. STAT Daily Recap 2018:1. [Ref.ID 102725]

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

Anónimo. Cannabinoid-based drug improved symptoms in adults with Tourette syndrome in phase 2 trial. DIA Daily 2018;10 de abril:3. [Ref.ID 102508]

Mershon E. STAT Plus: It’s not over: After defeat on ‘right to try,’ GOP vows to renew push. STAT Daily Recap 2018:2. [Ref.ID 102468]

Harrington M, Sigal EV. Opinion: ‘Right-to-try’ law threatens patient safety and rational drug development. STAT Daily Recap 2018:6. [Ref.ID 102467]

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon Ch, Harden M, Lennon N, Gabriel S, Rodig S, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217-21. [Ref.ID 101662]

Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2017;37:429-39. [Ref.ID 101410]

Anónimo. Vanucizumab fails to meet primary endpoint of progression-free survival for metastatic colorectal cancer patients. DIA Daily 2016:3. [Ref.ID 100838]

Anónimo. Kite Pharma’s experimental cancer therapy shows encouraging results, but doubts remain. DIA Daily 2016:7. [Ref.ID 100762]

Margulies KB, Hernández AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kieman MS, Felker M, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP, for the NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500-8. [Ref.ID 100686]

Dal-Ré R. Desarrollo clínico de nuevos medicamentos. Seguridad de los ensayos clínicos en voluntarios sanos. Med Clin (Barc) 2016;147:154-6. [Ref.ID 100648]

Mayor S. “Impressive results” in stem cell treatment for multiple sclerosis. BMJ 2016;353:i3269. [Ref.ID 100429]

Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016;387:1551-60. [Ref.ID 100228]

Rajkumar SV. Daratumumab in multiple myleoma. Lancet 2016;387:1490-2. [Ref.ID 100220]